Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery.

We have previously documented the safety of 1 unit (50 gram) of human polymerized hemoglobin (Poly SFH-P) in healthy volunteers. This report describes the first patient trial to assess the therapeutic benefit of Poly SFH-P in acute blood loss. Thirty-nine patients received 1 (n = 14), 2 (n = 2), 3 (n = 15), or 6 (n = 8) units of Poly SFH-P instead of red cells as part of their blood replacement after trauma and urgent surgery. There were no safety issues related to the infusion of Poly SFH-P. The plasma hemoglobin concentration ([Hb]) after the infusion of 6 units (300 gram) of Poly SFH-P was 4.8 +/- 0.8 g/dL (mean +/- SD). Although the red cell [Hb] fell to 2.9 +/- 1.2 g/dL, the total [Hb] was maintained at 7.5 +/- 1.2 g/dL. Poly SFH-P maintained total [Hb], despite the marked fall in red cell [Hb] due to blood loss. The utilization of O2 (extraction ratio) was 27 +/- 16% from the red cells and 37 +/- 13% from the Poly SFH-P. Twenty-three patients (59%) avoided allogeneic transfusions during the first 24 hours after blood loss. Poly SFH-P effectively loads and unloads O2 and maintains total hemoglobin in lieu of red cells after acute blood loss, thereby reducing allogeneic transfusions. Poly SFH-P seems to be a clinically useful blood substitute.

[1]  E. Moore,et al.  CLINICAL UTILITY OF HUMAN POLYMERIZED HEMOGLOBIN AS A BLOOD SUBSTITUTE FOLLOWING TRAUMA AND EMERGENT SURGERY: 576 , 1997 .

[2]  J. Siegel,et al.  Use of recombinant hemoglobin solution in reversing lethal hemorrhagic hypovolemic oxygen debt shock. , 1997, The Journal of trauma.

[3]  G. Moss,et al.  Clinical Development of Human Polymerized Hemoglobin as a Blood Substitute , 1996, World Journal of Surgery.

[4]  J. Fratantoni Points to consider on efficacy evaluation of hemoglobin‐ and perfluorocarbon‐based oxygen carriers. Center for Biologics Evaluation and Research , 1994, Transfusion.

[5]  R. Winslow,et al.  Acute changes in systemic blood pressure and urine output of conscious rats following exchange transfusion with diaspirin‐crosslinked hemoglobin solution , 1993, Transfusion.

[6]  J. Hess,et al.  Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. , 1993, Journal of applied physiology.

[7]  G. J. Crystal,et al.  Oxygen extraction ratio: a valid indicator of transfusion need in limited coronary vascular reserve? , 1991, The Journal of trauma.

[8]  J. Fratantoni Points to consider in the safety evaluation of hemoglobin‐based oxygen carriers , 1991, Transfusion.

[9]  G. Moss,et al.  Limits of cardiac compensation in anemic baboons. , 1988, Surgery.

[10]  G. Moss,et al.  Polymerized pyridoxylated hemoglobin: a red cell substitute with normal oxygen capacity. , 1984, Surgery.

[11]  G. Moss,et al.  Preparation and in vitro characteristics of polymerized pyridoxylated hemoglobin , 1983, Transfusion.

[12]  G. Moss,et al.  Red cell substitutes: hemoglobin solution or fluorocarbon? , 1982, The Journal of trauma.

[13]  J. Arnold,et al.  A clinical safety trial of stroma‐free hemoglobin , 1978, Clinical pharmacology and therapeutics.

[14]  J. L. Brandt,et al.  The effects of hemoglobin solutions on renal functions in man. , 1951, Blood.

[15]  J. H. Miller,et al.  The effect of hemoglobin on renal function in the human. , 1951, The Journal of clinical investigation.

[16]  Govind Singh,et al.  Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin. , 1996, Critical care medicine.

[17]  N. Laird,et al.  Perioperative red blood cell transfusion , 1988 .

[18]  W. R. Amberson,et al.  Clinical experience with hemoglobin-saline solutions. , 1947, Year book - American Philosophical Society.